Continue secukinumab after prior study, without safety issues
Part of Immune system & allergy clinical trials.
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent (or get a parent/guardian permission for youth) before any study checks
- You must be able to talk with the study team and follow study instructions
- You previously completed a secukinumab treatment study with Novartis (or were not finished due to non-safety, non-efficacy reasons)
- Your doctor believes you’re still benefiting and the benefits are worth the risks
- You cannot get the regular (marketed) secukinumab through your local prescription or insurance/reimbursement rules
- You must not have stopped the earlier study treatment early
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tests the safety of a drug called secukinumab (given as an injection under the skin) for people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if this treatment is safe for adults in India with this condition.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This study looks at how well secukinumab, a biologic medicine, works over the long term for children and teenagers with two types of juvenile arthritis: psoriatic arthritis (which also involves skin psoriasis) and enthesitis-related arthritis (which causes pain where tendons meet bones). It uses data from a German registry to see if the treatment is effective and safe in real-world settings.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
Hear when a new Autoimmunity, Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.